What is Signify Bio?
Founded in 2025, Signify Bio operates at the intersection of synthetic biology and therapeutic delivery. The company specializes in in situ protein therapeutics, a methodology that enables the human body to act as its own bioreactor. By utilizing its proprietary SEND (Signal peptide Engineered Nucleic acid Design) platform and iPhos lipid nanoparticles, Signify Bio facilitates the targeted and localized delivery of therapeutic proteins. This technological framework, developed in collaboration with the University of Texas Southwestern Medical Center, represents a significant departure from traditional systemic drug delivery, offering the potential for higher efficacy and reduced off-target effects in the treatment of complex genetic conditions.
How much funding has Signify Bio raised?
Signify Bio has raised a total of $15M across 1 funding round:
Other Financing Round
$15M
Other Financing Round (2025): $15M with participation from Danaher, Eli Lilly, BrightEdge, and Actium Group
Key Investors in Signify Bio
Danaher
Danaher Corporation provides integrated solutions across the biotechnology and life sciences sectors, offering specialized equipment and bioprocess technologies that streamline therapeutic development.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical leader focused on the discovery and commercialization of prescription medicines in areas including oncology, immunology, and neuroscience.
BrightEdge
BrightEdge is the innovation and impact investment arm of the American Cancer Society, dedicated to funding scalable solutions that address critical unmet needs in cancer treatment.
What's next for Signify Bio?
With this recent capital injection, Signify Bio is poised to accelerate its pipeline development and expand its research infrastructure. The strategic focus will likely center on scaling the manufacturing processes for its iPhos nanoparticle delivery systems and advancing lead candidates toward preclinical milestones. As the company matures, the integration of its proprietary platforms into broader therapeutic applications will be critical for maintaining its competitive edge in the biotechnology sector. Investors are closely monitoring the firm's ability to translate its innovative engineering into scalable, clinical-grade solutions that address significant unmet medical needs in the oncology and immunology landscapes.
See full Signify Bio company page
